| Company Name: |
Alabiotech Inc. |
| Tel: |
001-619-354-5251 |
| Email: |
sales@alabiotech-e.com |
| Company Name: |
Adachibio Inc. |
| Tel: |
+81-8027837258; |
| Email: |
sales@adachibio.com |
| Company Name: |
Nextpeptide Inc |
| Tel: |
+86-0571-81612335 +8613336028439 |
| Email: |
sales@nextpeptide.com |
- VEL-0230
-
- $1980.00
-
2026-07-27
- CAS:221144-20-3
- Purity:
- Supply Ability: 10g
|
| | NC 2300 Basic information |
| Product Name: | NC 2300 | | Synonyms: | NC 2300;VEL 0230;(2S,3S)-3-[[[(1S)-3-Methyl-1-[(2-methylpropoxy)methyl]butyl]amino]carbonyl]-2-oxiranecarboxylic acid sodium salt (1:1);sodium (2S,3S)-3-(((S)-1-isobutoxy-4-methylpentan-2-yl)carbamoyl)oxirane-2-carboxylate | | CAS: | 221144-20-3 | | MF: | C14H26NNaO5 | | MW: | 311.35 | | EINECS: | | | Product Categories: | peptides;Pepetides | | Mol File: | 221144-20-3.mol |  |
| | NC 2300 Chemical Properties |
| | NC 2300 Usage And Synthesis |
| Uses | NC 2300 (VEL-0230)is a selective and orally active cysteine cathepsin inhibitor with the IC50 values of 284, 34.5, and 186 nM for cathepsin B, K, and S, respectively.NC 2300 can be used for study of diseases involving bone mineral disorders[1][2]. | | References | [1] Aoki T,et al. Cathepsin B, K, and S are expressed in cerebral aneurysms and promote the progression of cerebral aneurysms. Stroke. 2008;39(9):2603-2610. DOI:10.1161/STROKEAHA.107.513648
[2] Hirai T, et al. Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation [published correction appears in J Immunol. 2014 May 15;192(10):4933]. J Immunol. 2013;190(9):4805-4811. DOI:10.4049/jimmunol.1200901 |
| | NC 2300 Preparation Products And Raw materials |
|